Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 154

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Blood (2019) 134 (Supplement_1): 846.

https://doi.org/10.1182/blood-2019-122980

Published: 2019

Journal Articles

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Nils Picker, MSc, Alexander T Cohen, MBBS, MSc, MD, Anthony Maraveyas, MD PhD, Jan Beyer-Westendorf, MD, Agnes Yuet Ying Lee, MD MSc, FRCPC, Lorenzo G Mantovani, Yoriko De Sanctis, MS, Khaled Abdelgawwad, Samuel Fatoba, Miriam Bach, Thomas Wilke, Prof. Dr. rer. oec.

Blood (2019) 134 (Supplement_1): 2159.

https://doi.org/10.1182/blood-2019-128095

Published: 2019

Journal Articles

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Natalia Scaramellini, MD, Carola Arighi, MD, Alessia Marcon, MD, Dario Consonni, MD, Elena Cassinerio, MD, Giovanna Graziadei, MD, Maria Domenica Cappellini, MD, Irene Motta, MD

Blood (2019) 134 (Supplement_1): 3542.

https://doi.org/10.1182/blood-2019-130237

Published: 2019

Journal Articles

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Andrea Piolatto, MS, Carmen Gaglioti, MD, Filomena Longo, MD, Silvia De Francia, PhD, Sarah Allegra, PhD, Paola Berchialla, PhD, Antonio Piga

Blood (2019) 134 (Supplement_1): 3547.

https://doi.org/10.1182/blood-2019-122030

Published: 2019

Journal Articles

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

Blood (2019) 134 (Supplement_1): 2843.

https://doi.org/10.1182/blood-2019-126661

Published: 2019

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study

Chandy C. John, MDMS, Robert Opoka, MMED, Teresa Latham, MA, Heather Hume, MDFRCPC, Maria Nakafeero, Phillip Kasirye, Christopher Ndugwa, Adam Lane, PhD, Russell E. Ware, MD PhD

Blood (2019) 134 (Supplement_1): 520.

https://doi.org/10.1182/blood-2019-125128

Published: 2019

Journal Articles

Intravenous Iron Infusions in Pediatric Patients: A Single Institution Assessment of Efficacy and Adverse Effects of IV Iron Infusions

Jennifer A Nestor, MD, Faraz A Afridi, Richard Suarez, BS, Joey Bou Karem, BS, Michael Hardiman, BSN, Krystal Hunter, MBA, Christine Rickette, RN, Rafat Ahmed, MBBS

Blood (2019) 134 (Supplement_1): 5872.

https://doi.org/10.1182/blood-2019-123800

Published: 2019

Journal Articles

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Guy Young, MD, Anthonie WA. Lensing, MD PhD, Paul Monagle, MBBS, MSc, Christoph Male, MD, Dagmar Kubitza, MD

Blood (2019) 134 (Supplement_1): 164.

https://doi.org/10.1182/blood-2019-124873

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Ruihua Mi, Lin Chen, MD, Xudong Wei, PhD, Xiaojiao WANG, Yongping Song, MD

Blood (2019) 134 (Supplement_1): 3865.

https://doi.org/10.1182/blood-2019-128431

Published: 2019

Journal Articles

Comparing Costs Associated to Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy in HCMV-Seropositive Patients Who Undergone to Hemopoietic Stem Cells Transplantation

Oscar Borsani, MD, Daniele Lilleri, Elisa Gabanti, Gabriela Cassinelli, Anna Amelia Colombo, MD, Daniela Caldera, MD, Emilio Paolo Alessandrino, MD, Paolo Bernasconi, MD

Blood (2019) 134 (Supplement_1): 5643.

https://doi.org/10.1182/blood-2019-124121

Published: 2019

Journal Articles

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

Haixia Guo, MD PhD

Blood (2019) 134 (Supplement_1): 4920.

https://doi.org/10.1182/blood-2019-126350

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

Take Control. Period. - Needs Assessment Leading to the Development of a Digital Quality Improvement Intervention Designed to Enhance Adherence to Tranexamic Acid and Iron Supplementation in Women with Heavy Menstrual Bleeding

Ying Ling, BMSc, MD, Filomena Meffe, MD MSc, Deborah Robertson, MD, Jessica Petrucci, MSc, Georgina Floros, RN, Paula D. James, MD, Jeffrey Mosko, MD MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 5868.

https://doi.org/10.1182/blood-2019-122521

Published: 2019

Journal Articles

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Bradley Mason, Carla M. Mamolo, PhD, Chloe Johnson, Andrea Viqueira, MD, Adam Gater, Alexander Russell-Smith, Sophi Tatlock, Richa Shah, PharmD, RPh, Joseph C Cappelleri, PhD MPH, MS

Blood (2019) 134 (Supplement_1): 5918.

https://doi.org/10.1182/blood-2019-123444

Published: 2019

Journal Articles

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Blood (2019) 134 (Supplement_1): 1130.

https://doi.org/10.1182/blood-2019-124234

Published: 2019

Journal Articles

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

William Knoll, BSc, Ranjeeta Mallick, PhD MSc, BSc, Philip S. Wells, MDMSc,FRCP, Marc Carrier, MD

Blood (2019) 134 (Supplement_1): 1140.

https://doi.org/10.1182/blood-2019-128834

Published: 2019

Journal Articles

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Haley E. Ramsey, PhDMSc, Maria Arrate, MSc, Londa Fuller, Agnieszka E. Gorska, MSc, Kelli Boyd, DVM, PhD, Melissa A. Fischer, MSc, PhD, Aram Oganesian, PhD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1376.

https://doi.org/10.1182/blood-2019-125899

Published: 2019

NARROW

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Low-Dose Tamoxifen (LDTam) As a Breast Cancer (BC) Risk-Reduction Strategy in Lymphoma Survivors Exposed to Chest Radiation Therapy (RT) during Adolescence/Young Adulthood - a Randomized, Placebo-Controlled Double Blinded Phase IIb Trial

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Optimizing Hydroxyurea Dosing in Sickle Cell Anemia: The Uganda MTD Study

Intravenous Iron Infusions in Pediatric Patients: A Single Institution Assessment of Efficacy and Adverse Effects of IV Iron Infusions

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Comparing Costs Associated to Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy in HCMV-Seropositive Patients Who Undergone to Hemopoietic Stem Cells Transplantation

Novel Pathogenic Genes and Rare Mutations of Congenital Factor V Deficiency: A Case Report

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Take Control. Period. - Needs Assessment Leading to the Development of a Digital Quality Improvement Intervention Designed to Enhance Adherence to Tranexamic Acid and Iron Supplementation in Women with Heavy Menstrual Bleeding

Preliminary Exploration of Patient Perspectives on Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial

Safety and Efficacy of Apixaban Thromboprophylaxis in Cancer Patients with Metastatic Disease: A Subgroup Analysis of the Avert Trial

Oral Azacitidine and Cedazuridine Approximate Azacitidine Efficacy in a Murine Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only